Fuente: FierceBiotech Seattle’s Adaptive Biotechnologies is linking up with Pfizer on two non-exclusive pacts that leverage the biotech’s bespoke T-cell receptor discovery engine and large-scale immune receptor antigen-mapping data. At the same time, Dren Bio said it has expanded a strategic collaboration with Sanofi in a bid to discover and develop a potential next-generation B-cell depleting therapy for “various autoimmune diseases.”